Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification and validation of biomarkers related to mismatch repair for prognosis prediction in glioma.

Frontiers in immunology·2026
Same author

Preclinical Evaluation of <sup>177</sup>Lu-Labeled Anti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer.

Molecular pharmaceutics·2026
Same author

A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.

American journal of hematology·2026
Same author

Comparative analysis of GPT-4o as a representative multimodal large language model and human fitters in orthokeratology lens fitting: Assessing accuracy, efficiency and cost-effectiveness in initial lens parameter selection.

Acta ophthalmologica·2026
Same author

Development and Evaluation of an Albumin-Binding GPC3-Targeting Peptide for PET Imaging of Hepatocellular Carcinoma.

Molecular pharmaceutics·2026
Same author

Microplastic co-pollution in food systems: interaction mechanisms, migration, removal technologies, and environmental linkages.

Food research international (Ottawa, Ont.)·2026

Related Experiment Video

Updated: Jun 10, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

CD70-targeted platform for diagnosing and treating multiple myeloma.

Jun Li1, Haoyi Yan1, Xiaoyan Wang1

  • 1Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.

Journal for Immunotherapy of Cancer
|June 8, 2026
PubMed
Summary

A new theranostic pair targeting CD70 shows promise for multiple myeloma (MM). The imaging agent [89Zr]Zr-DFO-ABDB6 and therapeutic [177Lu]Lu-DOTA-ABDB6 effectively image and treat MM in preclinical models.

Keywords:
AntibodyBiomarkerMultiple Myeloma

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

Related Experiment Videos

Last Updated: Jun 10, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Therapy

Background:

  • CD70 is overexpressed in multiple myeloma (MM), making it a viable target for theranostic applications.
  • Current treatment strategies for MM have limitations, necessitating novel approaches.

Purpose of the Study:

  • To develop and evaluate a CD70-targeted theranostic pair for imaging and treating MM.
  • The pair consists of an immuno-PET tracer ([89Zr]Zr-DFO-ABDB6) and a therapeutic agent ([177Lu]Lu-DOTA-ABDB6).

Main Methods:

  • Confirmed CD70 expression in MM patient samples and xenografts.
  • Developed and radiolabeled nanobody derivative ABDB6 with 89Zr and 177Lu.
  • Assessed pharmacokinetics, biodistribution, toxicity, and therapeutic efficacy in MM mouse models.

Main Results:

  • [89Zr]Zr-DFO-ABDB6 demonstrated high tumor uptake in MM models.
  • [177Lu]Lu-DOTA-ABDB6 at low doses (40-80 µCi) suppressed tumor growth and improved survival.
  • Higher doses of [177Lu]Lu-DOTA-ABDB6 caused transient toxicity; tumor relapse occurred after single-dose treatment.

Conclusions:

  • The CD70-targeted theranostic pair enables precise imaging and effective radiotherapy for MM.
  • Low-dose [177Lu]Lu-DOTA-ABDB6 is safe and effective, supporting clinical translation.
  • Further research into optimized dosing regimens or alpha-emitters is warranted to enhance treatment durability.